Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1996 Sep;119(2):229–232. doi: 10.1111/j.1476-5381.1996.tb15975.x

Neuropeptide Y Y2 receptor-mediated attenuation of neurogenic plasma extravasation acting through pertussis toxin-sensitive mechanisms.

X J Yu 1, M A Moskowitz 1
PMCID: PMC1915851  PMID: 8886402

Abstract

1. The effects of neuropeptide Y (NPY) receptor agonists (administered intravenously) were examined on plasma protein ([125I]-bovine serum albumin) leakage within dura mater evoked by unilateral trigeminal ganglion stimulation (0.6 mA, 5 ms, 5 Hz, 5 min), capsaicin (1 mumol kg-1, i.v.) or substance P (1 nmol kg-1, i.v.) in anaesthetized Sprague-Dawley rats. 2. NPY (EC50: 5.6 nmol kg-1) and NPY fragment 13-36 [NPY (13-36)] (ED50: 4.3 nmol kg-1), an NPY Y2 receptor agonist, dose-dependently attenuated [125I]-bovine serum albumin extravasation from meningeal vessels when administered 10 min prior to electrical stimulation. [Leu31, Pro34]-NPY, an NPY Y1 and Y3 receptor agonist, inhibited the response at a higher dose only (23 nmol kg-1) (P < 0.05). 3. NPY also significantly decreased plasma protein extravasation induced by capsaicin (1 mumol kg-1) but not by substance P (1 nmol kg-1). 4. Pertussis toxin (20 micrograms kg-1, administered intracisternally 48 h prior to stimulation) blocked completely the inhibitory effect of NPY and NPY (13-36) but did not inhibit extravasation alone. 5. We conclude that NPY inhibits neurogenically-mediated plasma protein extravasation acting through presynaptic pertussis toxin-sensitive NPY Y2 receptors, possibly by inhibition of neuropeptide release from perivascular trigeminovascular afferents.

Full text

PDF
229

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Buzzi M. G., Moskowitz M. A., Peroutka S. J., Byun B. Further characterization of the putative 5-HT receptor which mediates blockade of neurogenic plasma extravasation in rat dura mater. Br J Pharmacol. 1991 Jun;103(2):1421–1428. doi: 10.1111/j.1476-5381.1991.tb09805.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Buzzi M. G., Moskowitz M. A. The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br J Pharmacol. 1990 Jan;99(1):202–206. doi: 10.1111/j.1476-5381.1990.tb14679.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Colmers W. F., Pittman Q. J. Presynaptic inhibition by neuropeptide Y and baclofen in hippocampus: insensitivity to pertussis toxin treatment. Brain Res. 1989 Sep 25;498(1):99–104. doi: 10.1016/0006-8993(89)90403-4. [DOI] [PubMed] [Google Scholar]
  4. Cutrer F. M., Schoenfeld D., Limmroth V., Panahian N., Moskowitz M. A. Suppression by the sumatriptan analogue, CP-122,288 of c-fos immunoreactivity in trigeminal nucleus caudalis induced by intracisternal capsaicin. Br J Pharmacol. 1995 Mar;114(5):987–992. doi: 10.1111/j.1476-5381.1995.tb13302.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Dimitriadou V., Buzzi M. G., Moskowitz M. A., Theoharides T. C. Trigeminal sensory fiber stimulation induces morphological changes reflecting secretion in rat dura mater mast cells. Neuroscience. 1991;44(1):97–112. doi: 10.1016/0306-4522(91)90253-k. [DOI] [PubMed] [Google Scholar]
  6. Dimitriadou V., Buzzi M. G., Theoharides T. C., Moskowitz M. A. Ultrastructural evidence for neurogenically mediated changes in blood vessels of the rat dura mater and tongue following antidromic trigeminal stimulation. Neuroscience. 1992;48(1):187–203. doi: 10.1016/0306-4522(92)90348-6. [DOI] [PubMed] [Google Scholar]
  7. Duggan A. W., Hope P. J., Lang C. W. Microinjection of neuropeptide Y into the superficial dorsal horn reduces stimulus-evoked release of immunoreactive substance P in the anaesthetized cat. Neuroscience. 1991;44(3):733–740. doi: 10.1016/0306-4522(91)90092-3. [DOI] [PubMed] [Google Scholar]
  8. Giuliani S., Maggi C. A., Meli A. Prejunctional modulatory action of neuropeptide Y on peripheral terminals of capsaicin-sensitive sensory nerves. Br J Pharmacol. 1989 Oct;98(2):407–412. doi: 10.1111/j.1476-5381.1989.tb12611.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Goadsby P. J., Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 1993 Jan;33(1):48–56. doi: 10.1002/ana.410330109. [DOI] [PubMed] [Google Scholar]
  10. Grundemar L., Grundström N., Johansson I. G., Andersson R. G., Håkanson R. Suppression by neuropeptide Y of capsaicin-sensitive sensory nerve-mediated contraction in guinea-pig airways. Br J Pharmacol. 1990 Mar;99(3):473–476. doi: 10.1111/j.1476-5381.1990.tb12952.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Grundemar L., Håkanson R. Neuropeptide Y effector systems: perspectives for drug development. Trends Pharmacol Sci. 1994 May;15(5):153–159. doi: 10.1016/0165-6147(94)90076-0. [DOI] [PubMed] [Google Scholar]
  12. Hua X. Y., Boublik J. H., Spicer M. A., Rivier J. E., Brown M. R., Yaksh T. L. The antinociceptive effects of spinally administered neuropeptide Y in the rat: systematic studies on structure-activity relationship. J Pharmacol Exp Ther. 1991 Jul 1;258(1):243–248. [PubMed] [Google Scholar]
  13. Lee W. S., Limmroth V., Ayata C., Cutrer F. M., Waeber C., Yu X., Moskowitz M. A. Peripheral GABAA receptor-mediated effects of sodium valproate on dural plasma protein extravasation to substance P and trigeminal stimulation. Br J Pharmacol. 1995 Sep;116(1):1661–1667. doi: 10.1111/j.1476-5381.1995.tb16388.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Mantyh P. W., Allen C. J., Rogers S., DeMaster E., Ghilardi J. R., Mosconi T., Kruger L., Mannon P. J., Taylor I. L., Vigna S. R. Some sensory neurons express neuropeptide Y receptors: potential paracrine inhibition of primary afferent nociceptors following peripheral nerve injury. J Neurosci. 1994 Jun;14(6):3958–3968. doi: 10.1523/JNEUROSCI.14-06-03958.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Markowitz S., Saito K., Moskowitz M. A. Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not brain. J Neurosci. 1987 Dec;7(12):4129–4136. doi: 10.1523/JNEUROSCI.07-12-04129.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Modin A., Pernow J., Lundberg J. M. Evidence for two neuropeptide Y receptors mediating vasoconstriction. Eur J Pharmacol. 1991 Oct 15;203(2):165–171. doi: 10.1016/0014-2999(91)90711-x. [DOI] [PubMed] [Google Scholar]
  17. Moskowitz M. A. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol Sci. 1992 Aug;13(8):307–311. doi: 10.1016/0165-6147(92)90097-p. [DOI] [PubMed] [Google Scholar]
  18. Moskowitz M. A. The neurobiology of vascular head pain. Ann Neurol. 1984 Aug;16(2):157–168. doi: 10.1002/ana.410160202. [DOI] [PubMed] [Google Scholar]
  19. Narváez J. A., Aguirre J. A., Van der Ploeg I., Fuxe K. Intracerebroventricularly administered pertussis toxin blocks the central vasopressor action of neuropeptide Y(13-36) in the awake unrestrained male rat. Neurosci Lett. 1992 Jun 22;140(2):273–276. doi: 10.1016/0304-3940(92)90119-r. [DOI] [PubMed] [Google Scholar]
  20. Potter E. K., McCloskey M. J. [Leu31, Pro34] NPY, a selective functional postjunctional agonist at neuropeptide-Y receptors in anaesthetised rats. Neurosci Lett. 1992 Jan 6;134(2):183–186. doi: 10.1016/0304-3940(92)90512-6. [DOI] [PubMed] [Google Scholar]
  21. Saito K., Markowitz S., Moskowitz M. A. Ergot alkaloids block neurogenic extravasation in dura mater: proposed action in vascular headaches. Ann Neurol. 1988 Dec;24(6):732–737. doi: 10.1002/ana.410240607. [DOI] [PubMed] [Google Scholar]
  22. Scholz K. P., Miller R. J. Analysis of adenosine actions on Ca2+ currents and synaptic transmission in cultured rat hippocampal pyramidal neurones. J Physiol. 1991 Apr;435:373–393. doi: 10.1113/jphysiol.1991.sp018515. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Scholz K. P., Miller R. J. GABAB receptor-mediated inhibition of Ca2+ currents and synaptic transmission in cultured rat hippocampal neurones. J Physiol. 1991 Dec;444:669–686. doi: 10.1113/jphysiol.1991.sp018900. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Takahashi T., Ichinose M., Yamauchi H., Miura M., Nakajima N., Ishikawa J., Inoue H., Takishima T., Shirato K. Neuropeptide Y inhibits neurogenic inflammation in guinea pig airways. J Appl Physiol (1985) 1993 Jul;75(1):103–107. doi: 10.1152/jappl.1993.75.1.103. [DOI] [PubMed] [Google Scholar]
  25. Wager-Pagé S. A., Raizada E., Veale W., Davison J. S. Peripheral modulation of duodenal and colonic motility and arterial pressure by neuropeptide Y, neuropeptide Y fragment 13-36, peptide YY, and pancreatic polypeptide in rats: cholinergic mechanisms. Can J Physiol Pharmacol. 1993 Oct-Nov;71(10-11):768–775. doi: 10.1139/y93-115. [DOI] [PubMed] [Google Scholar]
  26. Wiley J. W., Gross R. A., Lu Y. X., Macdonald R. L. Neuropeptide Y reduces calcium current and inhibits acetylcholine release in nodose neurons via a pertussis toxin-sensitive mechanism. J Neurophysiol. 1990 Jun;63(6):1499–1507. doi: 10.1152/jn.1990.63.6.1499. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES